Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week!

Published on 15/03/19 at 10:47am

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia Pharmaceuticals in relation to Nuplazid, a psychosis drug for those with Parkinson’s disease.

Personal genomics company 23andMe, this week announced they would offer reports on customer’s likelihood they would develop type 2 diabetes. Meanwhile researchers published results showing a new class of drugs offered similar efficacy to statins.

The news came after Sandoz CEO Francis Richard announced he would be stepping down from his position as CEO. The relatively relaxed week comes in contrast to the ongoing Brexit affair. Check out this week's top 10!

10. 23andMe to offer genetic reports on diabetes

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 diabetes.

9. PV futures: Pharmacovigilance as a solution to the challenges of tomorrow

Louis Goss asks what the future might hold for the safety of pharmaceuticals and looks into why crucial pharmacovigilance practices offer solutions in an increasingly uncertain world.

8. Healthcare industry could take up to five years to stabilise after no-deal Brexit

The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to pharmaceutical industry professionals surveyed by GlobalData.

7. FDA advisory panel recommends Sanofi's dengue vaccine in children, but rejects its use in adults

Dengvaxia, Sanofi’s vaccine for dengue fever, has been burdened with further negative scrutiny after the FDA’s vaccine advisory panel passed mixed judgements on its efficacy and safety in adults and children with the disease.

6. Dutch pharmacists to circumvent Novartis cancer drug market exclusivity

Dutch pharmacists have vowed to circumvent rules enforcing Novartis’ market exclusivity for radioactive cancer drug Lutathera.

5. New class of drugs offer alternative to statins

A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study published in the New England Journal of Medicine.

4. FDA approves Pfizer's Herceptin biosimilar Trazimera

Patients in the US will now be able to access another biosimilar version of Herceptin (trastuzumab) with the FDA approval of Pfizer’s Trazimera in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

3. Sandoz CEO Richard Francis to step down

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ in the role, citing “personal reasons” for his departure, its parent company announced in a statement.

2. FDA approves first diagnostic tool to target triple-negative breast cancer patients

Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer (TNBC) who are eligible for treatment with the company’s immunotherapy combo of Tecentriq (atezolizumab) plus Abraxane chemotherapy.

1. US DoJ launch investigation into Acadia Pharmaceuticals

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia Pharmaceuticals in relation to Nuplazid, a psychosis drug for those with Parkinson’s disease.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches